stockrow
Saturday 7 November 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024.
- Revenue
- +4,895.9%
- EPS
- +426.5%
- Free cash flow
- +25.7%
- Total debt
- +3.27%
Quarter to September 2026, against a year earlier
2.30
0.21
+10.05%
Follow ALEC
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 1 | 3 | 5 | 3 | 1 | 2 | 1 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 2.08 | 1.62 | 2.17 | 0.32 | (0.68) | (2.20) | (5.15) |
P/S ratio |
7.64 | 7.64 | 7.64 | 50.13 | 55.76 | 8.02 | 5.62 | 6.89 | 1.82 | 7.64 |
Altman Z″-Score (non-manufacturers) |
— | 4.05 | 3.37 | 1.97 | 0.60 | 3.43 | 2.09 | (0.98) | (3.26) | (9.85) |
P/FCF ratio |
1.68 | 1.68 | 1.68 | 0.00 | 0.00 | 5.62 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | (3.91) | — | — | — |
P/Operating CF |
(11.97) | (11.97) | (11.97) | (36.90) | (24.69) | (33.71) | (15.34) | (14.52) | (3.32) | (3.85) |
P/B ratio |
0.00 | 0.00 | 0.00 | 5.46 | 4.40 | 5.52 | 3.50 | 4.99 | 1.44 | 5.24 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 5.46 | 4.40 | 5.52 | 3.50 | 4.99 | 1.44 | 5.24 |
EV/Sales |
(2.86) | (2.86) | (2.86) | 35.75 | 38.60 | 4.70 | 0.61 | 1.65 | (2.12) | (4.07) |
EV/EBITDA |
1.40 | 1.40 | 1.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 0.56 |
EV/Operating CF |
(0.62) | (0.62) | (0.62) | (7.64) | (4.88) | 3.26 | (3.98) | (0.87) | 0.93 | 0.47 |
EV/FCF |
(0.63) | (0.63) | (0.63) | (6.62) | (4.74) | 3.29 | (3.31) | (0.86) | 0.92 | 0.47 |
Quick Ratio |
33.81 | 8.49 | 6.06 | 5.70 | 6.07 | 5.32 | 7.63 | 3.08 | 3.31 | 3.68 |
Current Ratio |
33.90 | 8.50 | 6.11 | 5.77 | 6.19 | 5.37 | 7.74 | 3.18 | 3.40 | 3.83 |
Net Debt/EBITDA |
3.40 | 1.01 | 5.16 | 2.80 | 1.93 | 25.52 | 5.13 | 3.47 | 2.68 | 1.61 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 11.39% | 10.50% | 5.84% | 5.50% | 0.00% | 2.00% | 3.30% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.25 | 0.19 | 0.16 | 0.20 | 0.00 | 0.07 | 0.32 |
Asset Turnover |
0.00 | 0.03 | 0.10 | 0.06 | 0.05 | 0.32 | 0.17 | 0.14 | 0.18 | 0.06 |
Operating CF/Net income |
0.86 | 0.55 | (2.44) | 0.94 | 0.88 | (8.22) | 0.15 | 1.41 | 1.93 | 1.29 |
Capex/Depreciation |
(11.19) | (1.18) | (1.85) | (2.74) | (0.64) | (0.31) | (0.56) | 0.37 | 0.23 | (0.01) |
| 39.28% | 84.43% | 69.93% | (216.52%) | (82.30%) | (12.79%) | (51.75%) | (74.81%) | (91.24%) | (181.56%) | |
| (12.80%) | (27.52%) | (19.19%) | (28.86%) | (41.80%) | (5.58%) | (16.64%) | (18.50%) | (21.84%) | (37.54%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(28.94%) | (15.59%) | (20.40%) | (32.00%) | (49.59%) | (5.70%) | (20.26%) | (31.82%) | (37.57%) | (68.79%) |
Average Days of Receivables |
191.27 | 19,568.10 | 0.00 | 0.00 | 0.00 | 13.03 | 7.07 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
3,287.02% | 800.83% | 263.87% | 473.76% | 743.53% | 91.46% | 157.48% | 197.93% | 184.91% | 584.77% |
Selling, General and Administrative Expense of Revenue |
450.48% | 174.11% | 43.12% | 165.39% | 281.56% | 26.58% | 45.68% | 58.40% | 59.28% | 256.53% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
471.88% | 143.35% | 25.02% | 76.73% | 144.67% | 19.69% | 34.54% | 44.09% | 39.24% | 126.67% |
Graham Net Nets |
0.46 | 0.46 | 0.46 | 0.12 | 0.17 | 0.14 | 0.20 | 0.12 | 0.46 | 0.02 |
Graham Number |
0.00 | 0.00 | 29.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(25.51%) | (25.51%) | (25.51%) | (9.87%) | (16.13%) | (2.28%) | (17.69%) | (19.40%) | (65.08%) | (89.10%) |
Free Cash Flow Yield |
59.42% | 59.42% | 59.42% | (10.77%) | (14.60%) | 17.78% | (3.26%) | (27.88%) | (126.63%) | (114.56%) |
Revenue per Share |
0.06 | 0.41 | 2.45 | 0.34 | 0.27 | 2.58 | 1.62 | 1.16 | 1.04 | 0.20 |
Operating CF per Share |
(1.81) | (1.94) | 11.28 | (1.61) | (2.14) | 3.71 | (0.25) | (2.20) | (2.38) | (1.79) |
Capex per Share |
(0.31) | (0.09) | (0.17) | (0.25) | (0.06) | (0.04) | (0.05) | (0.03) | (0.01) | 0.00 |
Free Cash Flow per Share |
(2.13) | (2.03) | 11.11 | (1.86) | (2.21) | 3.67 | (0.30) | (2.23) | (2.39) | (1.79) |
Cash per Share |
7.09 | 3.55 | 25.69 | 5.72 | 5.32 | 9.14 | 8.64 | 6.55 | 4.28 | 2.49 |
Shareholders Equity per Share |
0.00 | 2.78 | 10.01 | 3.15 | 3.44 | 3.74 | 2.60 | 1.60 | 1.31 | 0.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 2.78 | 10.01 | 3.15 | 3.44 | 3.74 | 2.60 | 1.60 | 1.31 | 0.30 |
Free Cash Flow |
(15.24) | (18.57) | 125.58 | (114.57) | (171.77) | 295.30 | (24.45) | (186.54) | (231.16) | (184.07) |
Working Capital |
49.68 | 205.57 | 245.23 | 295.47 | 353.42 | 610.16 | 632.63 | 387.86 | 299.76 | 196.95 |
Capital Expenditures |
(2.25) | (0.80) | (1.88) | (15.26) | (5.03) | (3.25) | (4.12) | (2.38) | (1.25) | (0.04) |
Net Current Asset Value |
51.19 | 22.37 | 97.94 | 130.27 | 200.79 | 235.78 | 153.23 | 78.14 | 83.31 | 3.86 |
EV/EBIT |
1.38 | 1.38 | 1.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.47 | 0.55 |
Capex to Sales |
5.41 | 0.21 | 0.07 | 0.72 | 0.24 | 0.02 | 0.03 | 0.02 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.08 | 0.24 | 0.09 | 0.16 | 0.26 | 0.38 | 0.29 | (0.30) | (0.32) | 0.31 |
Cash ROIC |
(29.98%) | (32.07%) | 31.12% | (19.23%) | (23.46%) | 27.25% | (2.52%) | (27.31%) | (42.06%) | (62.11%) |
Accounts Receivable Turnover |
0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 1.99 | 26.78 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
100.23 | 100.23 | — | — | — | 103.81 | 4.99 | — | — | — |
Average Payables |
1.15 | 1.15 | 0.63 | 0.20 | 1.64 | 3.88 | 4.47 | 3.98 | 3.00 | 1.95 |
Average Assets |
118.03 | 118.03 | 272.21 | 365.14 | 455.08 | 651.45 | 801.15 | 704.74 | 545.07 | 380.77 |
Average Common Equity |
(38.47) | (38.47) | (74.72) | 48.67 | 231.14 | 284.13 | 257.58 | 174.30 | 130.48 | 78.72 |
Columns are period end dates · fundamentals updated 5 Nov 2026